Determining efficacy and safety of the refocus scleral implant procedure for the treatment of presbyopia in plano presbyopes

Session Details

Session Title: Presbyopic Corrections

Session Date/Time: Monday 15/09/2014 | 16:30-18:30

Paper Time: 18:14

Venue: Boulevard F (Level 1)

First Author: : A.Cummings IRELAND

Co Author(s): :                  

Abstract Details

Purpose:

The Refocus scleral implant procedure is a procedure that is currently undergoing FDA investigation to determine efficacy and safety for the treatment of presbyopia in emmetropic presbyopes. The first clinical results are reported from a commercial site utilizing this procedure. Distance vision as well as uncorrected near vision is reported as well as clinical findings.

Setting:

Wellington Eye Clinic, Dublin, Ireland. Single surgeon.

Methods:

14 Eyes have been treated to date with 6 month outcomes. Pre-operative refraction was within ±0.75D of emmetropia and less than 1.00D of astigmatism. Patients were all presbyopic and mean age is 55 years of age. Reading vision was less than N12 pre-operatively. All required reading glasses pre-operatively.

Results:

6 Month data shows improved near vision for all eyes with no loss of distance visual acuity. Mean UCDVA is 6/6+ and mean sphere equivalent refraction was +0.37D. Mean pre-operative astigmatism 0.34DC. Mean pre-operative near vision was N12.85 and this improved to N7+ at the 6 month mark. All patients are free from reading glasses at the 6 month post-operative visit.

Conclusions:

Presbyopia has often been addressed with monovision or multifocality, both of which may contribute to reduced UCDVA. The Refocus procedure improves reading vision and rather than decreasing UCDVA, it improved UCDVA. It may be a good solution for presbyopia for the plano presbyope that is not prepared to compromise UCDVA.

Financial Interest:

NONE